中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
MiR-337-3p improves metabolic-associated fatty liver disease through regulation of metabolism

文献类型：期刊论文

作者Xu, Xiaoding2,3,4; Yu, Chuwei2,3; He, Hongxiu2,3,4; Pan, Xiangyu1,3; Hou, Aijun2,3; Feng, Jianxun3; Tan, Rongrong3; Gong, Likun2,3,4; Chen, Jing2,3,4; Ren, Jin2,3,4
刊名ISCIENCE
出版日期2023-11-17
卷号26期号:11页码:18
DOI10.1016/j.isci.2023.108352
通讯作者Chen, Jing(jingchen@simm.ac.cn) ; Ren, Jin(jren@cdser.simm.ac.cn)
英文摘要Epigenetic regulations play crucial roles in the pathogenesis of metabolic-associated fatty liver disease; therefore, elucidating the biological functions of differential miRNAs helps us to understand the pathogenesis. Herein, we discovered miR-337-3p was decreased in patients with NAFLD from Gene Expression Omnibus dataset, which was replicated in various cell and mouse models with lipid disorders. Subsequently, overexpression of miR-337-3p in vivo could ameliorate hepatic lipid accumulation, reduce fasting blood glucose, and improve insulin resistance. Meanwhile, we determined miR-337-3p might influence multiple genes involved in glycolipid metabolism through mass spectrometry detection, bioinformatics analysis, and experimental verification. Finally, we selected HMGCR as a representative example to investigate the molecular mechanism of miR-337-3p regulating these genes, where the seed region of miR-3373p bound to 30UTR of HMGCR to inhibit HMGCR translation. In conclusion, we discovered a new function of miR-337-3p in glycolipid metabolism and that might be a new therapeutic target of MAFLD.
WOS关键词MICRORNAS ; TRANSCRIPTION ; EXPRESSION
资助项目Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine[ZYYCXTD-D-202210] ; Foundation of Shanghai Science and Technology Committee[21DZ2291100]
WOS研究方向Science & Technology - Other Topics
语种英语
出版者CELL PRESS
WOS记录号WOS:001109727400001
源URL[http://119.78.100.183/handle/2S10ELR8/308119]  
专题新药研究国家重点实验室
通讯作者Chen, Jing; Ren, Jin
作者单位1.Soochow Univ, Coll Pharmaceut Sci, Dept Pharmaceut, Suzhou 215123, Peoples R China
2.Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China
3.Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Drug Safety Evaluat & Res, State Key Lab Drug Res, 501 Haike Rd, Shanghai 201203, Peoples R China
4.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
推荐引用方式
GB/T 7714		 Xu, Xiaoding,Yu, Chuwei,He, Hongxiu,et al. MiR-337-3p improves metabolic-associated fatty liver disease through regulation of metabolism[J]. ISCIENCE,2023,26(11):18.
APA Xu, Xiaoding.,Yu, Chuwei.,He, Hongxiu.,Pan, Xiangyu.,Hou, Aijun.,...&Ren, Jin.(2023).MiR-337-3p improves metabolic-associated fatty liver disease through regulation of metabolism.ISCIENCE,26(11),18.
MLA Xu, Xiaoding,et al."MiR-337-3p improves metabolic-associated fatty liver disease through regulation of metabolism".ISCIENCE 26.11(2023):18.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。